{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:44:50Z","timestamp":1784004290568,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601589"],"award-info":[{"award-number":["81601589"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874026"],"award-info":[{"award-number":["81874026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003397","name":"Huazhong University of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.biopha.2020.110377","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T04:54:26Z","timestamp":1592196866000},"page":"110377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity"],"prefix":"10.1016","volume":"129","author":[{"given":"Yuling","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110377_bib0005","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2020.110377_bib0010","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.21873\/anticanres.11614","article-title":"Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer","volume":"37","author":"Inadomi","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2020.110377_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/imt.14.111","article-title":"Rationale for combining immunotherapy with chemotherapy","volume":"7","author":"Dalgleish","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2020.110377_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2020.110377_bib0025","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.110377_bib0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","article-title":"Combining chemotherapy with PD-1 blockade in NSCLC","volume":"186","author":"Mathew","year":"2018","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.biopha.2020.110377_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumor heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110377_bib0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","article-title":"Doxorubicin: nanotechnological overviews from bench to bedside","volume":"22","author":"Cagel","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2020.110377_bib0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/bcr787","article-title":"Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER2\/neu in a murine mammary carcinoma model","volume":"6","author":"Eralp","year":"2004","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2020.110377_bib0050","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.intimp.2009.09.008","article-title":"Doxorubicin enhances CD4(+) T-cell immune responses by inducing expression of CD40 ligand and 4-1BB","volume":"9","author":"Park","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2020.110377_bib0055","first-page":"3572","article-title":"Adriamycin-induced modulation of host defenses in tumor-bearing mice","volume":"52","author":"Maccubbin","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110377_bib0060","first-page":"3689","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110377_bib0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.110377_bib0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.immuni.2013.07.017","article-title":"Autophagy and cellular immune responses","volume":"39","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2020.110377_bib0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2016.06.003","article-title":"A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery","volume":"235","author":"Bao","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2020.110377_bib0080","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41563-018-0093-6","article-title":"Dendritic cells in cancer immunotherapy","volume":"17","author":"Gall","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.biopha.2020.110377_bib0085","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/2159-8290.CD-18-1357","article-title":"Cancer vaccines: steering T cells down the right path to eradicate tumors","volume":"9","author":"Ott","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2020.110377_bib0090","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.biopha.2016.08.050","article-title":"Xenogeneic cell-based vaccine therapy for colorectal cancer: safety, association of clinical effects with vaccine-induced immune responses","volume":"83","author":"Seledtsova","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2020.110377_bib0095","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1021\/acsnano.5b01042","article-title":"Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma","volume":"9","author":"Guo","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2020.110377_bib0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2020.110377_bib0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2020.110377_bib0110","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2020.110377_bib0115","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN-\u03b3 and lymphocytes prevent primary tumor development and shape tumor immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110377_bib0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4049\/jimmunol.0900734","article-title":"Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism","volume":"183","author":"Shurin","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2020.110377_bib0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-011-1117-0","article-title":"Immunological effects of Taxol and Adryamicin in breast cancer patients","volume":"61","author":"Panis","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2020.110377_bib0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110377_bib0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1479-5876-7-58","article-title":"Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations","volume":"7","author":"Kaneno","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2020.110377_bib0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.1996.tb00920.x","article-title":"CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model","volume":"153","author":"Gool","year":"1996","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2020.110377_bib0145","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.4049\/jimmunol.1900593","article-title":"Downregulation of MHC class II by ubiquitination is required for the migration of CD206+ dendritic cells to skin-draining lymph nodes","volume":"203","author":"Majdoubi","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2020.110377_bib0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1208\/s12248-014-9675-7","article-title":"Gene-directed enzyme prodrug therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2020.110377_bib0155","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.110377_bib0160","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","article-title":"Foxp3 expressing CD4+ CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells","volume":"173","author":"Viguier","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2020.110377_bib0165","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110377_bib0170","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.110377_bib0175","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/sj.onc.1206457","article-title":"Angiogenesis, lymphangiogenesis, and melanoma metastasis","volume":"22","author":"Streit","year":"2003","journal-title":"Oncogene"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220305709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220305709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:57:25Z","timestamp":1760097445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220305709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":35,"alternative-id":["S0753332220305709"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110377","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110377"}}